Disease · MONDO_0005113

bacterial infectious disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bacterial infectious disease. Diseases, record MONDO_0005113. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005113

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bacterial infectious disease; Open Targets
Open Targets ID: MONDO_0005113; Open Targets
Other names: Bacteria caused disease or disorder, Bacteria disease or disorder, Bacteria infectious disease, bacterial disease, bacterial disorder, bacterial infection, infection, bacterial; Open Targets
Disease Ontology: DOID:104; Disease Ontology
MeSH: D001424; MeSH
NCI Thesaurus: C2890; NCI Thesaurus
Highest stage of its drugs: Approval, for 288 of its 384 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs384

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DALBAVANCIN	CHEMBL3301669	Protein	Approval	ATC and TTD	7	5	5	Drugs and targets
PIPERACILLIN	CHEMBL702	Small molecule	Approval	ATC and TTD	7	4	4	Drugs and targets
TAZOBACTAM	CHEMBL404	Small molecule	Approval	ATC, EMA Human Drugs and TTD	7	4	4	Drugs and targets
VANCOMYCIN	CHEMBL262777	Small molecule	Approval	ATC	5	4	4	Drugs and targets
MEROPENEM	CHEMBL127	Small molecule	Approval	ATC, EMA Human Drugs and TTD	6	3	3	Drugs and targets
AMOXICILLIN	CHEMBL1082	Small molecule	Approval	ATC and TTD	5	3	2	Drugs and targets
CEFTRIAXONE	CHEMBL161	Small molecule	Approval	ATC and TTD	5	2	2	Drugs and targets
CHLORHEXIDINE	CHEMBL790	Small molecule	Approval	TTD	3	2	2	Drugs and targets
SOLITHROMYCIN	CHEMBL1232510	Small molecule	Approval	ATC	3	2	2	Drugs and targets
TIGECYCLINE	CHEMBL376140	Small molecule	Approval	ATC and EMA Human Drugs	4	1	1	Drugs and targets

1 to 10 of 384

See all 384 drugs

Targets78

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 3	https://conductscience.org/library/genes/1441	Drugs and targets
PTGS1	Cyclooxygenase	3	Cyclooxygenase inhibitor	Unknown	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	3	Cyclooxygenase inhibitor	Unknown	https://conductscience.org/library/genes/5743	Drugs and targets
ATP4A	Potassium-transporting ATPase	2	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	2	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Approval	https://conductscience.org/library/genes/7153	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Unknown	https://conductscience.org/library/genes/1636	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/776	Drugs and targets

1 to 10 of 78

See all 78 targets

Trials41

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00627393	Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)	Phase 3	114	2014-12-23	Neutropenia, Infection	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT00608959	Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects	Phase 3	30	2010-01-25	Infection	CHLORHEXIDINE, OMIGANAN	Its record names the disease	ClinicalTrials.gov
NCT05217537	Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections	Phase 1	23	2026-03-09	Bacterial Infections	OMADACYCLINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02013141	Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)	Phase 1	22	2024-06-24	Gram-Positive Bacterial Infections	TELAVANCIN	Its record names the disease	ClinicalTrials.gov
NCT03587428	Effect of Two Toothpastes on Bacteria in Saliva	Not applicable	15	2019-07-15	Oral Health	SODIUM CITRATE, ZINC CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03651895	Metformin to Reduce Airway Glucose in COPD Patients	Phase 2	14	2025-02-18	Chronic Obstructive Pulmonary Disease	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT01401010	Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients	Phase 4	12	2012-06-05	Febrile Neutropenia	DORIPENEM	Its record names the disease	ClinicalTrials.gov
NCT01157533	Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients	Not applicable	1	2013-03-18	Infection	VANCOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT02208154	Ecological Effects of Decolonisation Strategies in Intensive Care	Phase 3	8,665		ICU-ecology (Multidrug Resistant Bacteria), ICU-acquired Bacteraemia	CHLORHEXIDINE, COLISTIN, NYSTATIN, TOBRAMYCIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02573610	Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery	Phase 3	576		Cataract Surgery	LEVOFLOXACIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 41

See all 41 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Granulocyte Arm vs Control Arm: Long-term Survival	20 of 56	30 of 58	114	NCT00627393	Trial comparisons
Granulocyte Arm vs Control Arm: serious adverse events	26 of 56	25 of 58	114	NCT00627393	Trial comparisons
Omiganan 1% Gel (Part 2) vs Chlorhexidine 2%/ Isopropyl Alcohol: Number of Subjects With Significantly Colonized Catheters, Defined as > or = to 15 Colony Forming Units- CFUs)	0 of 25	1 of 24	49	NCT00608959	Trial comparisons
Treatment Group vs Placebo Group: deaths from any cause	0 of 14	0 of 14	28	NCT03651895	Trial comparisons
Treatment Group vs Placebo Group: serious adverse events	0 of 14	1 of 14	28	NCT03651895	Trial comparisons
Doripenem 500 mg vs Doripenem 1000 mg: serious adverse events	0 of 5	0 of 6	11	NCT01401010	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25361023	RESULT	1	PubMed
24527370	RESULT	1	PubMed
40387400	DERIVED	1	PubMed
37815398	DERIVED	1	PubMed
36088952	DERIVED	1	PubMed
34905144	DERIVED	1	PubMed
32716292	DERIVED	1	PubMed
31318840	DERIVED	2	PubMed
31289068	DERIVED	1	PubMed
30347072	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005113

GET https://conductscience.org/api/diseases/v1/MONDO_0005113/drugs?page=2

API reference For AI assistants